Cymbalta Drug Class
Cymbalta (duloxetine) belongs to the SNRI (Serotonin-Norepinephrine Reuptake Inhibitor) class of medications, also referred to as SSNRI (Selective Serotonin-Norepinephrine Reuptake Inhibitor) in some literature. 1
Mechanism of Action
Duloxetine works by inhibiting the presynaptic reuptake of both serotonin and norepinephrine in the brain 2. This dual mechanism distinguishes SNRIs from SSRIs (which primarily affect serotonin) and gives them unique therapeutic properties for both mood disorders and pain conditions.
Clinical Context
The SNRI class includes several medications currently marketed in the United States:
- Venlafaxine
- Desvenlafaxine
- Duloxetine (Cymbalta)
- Levomilnacipran 2
Duloxetine is the only SNRI with FDA approval for treating generalized anxiety disorder in children and adolescents (age 7 and older) 2. It also has FDA approval for painful diabetic peripheral neuropathy 3.
Pharmacokinetics
Duloxetine has a sufficiently long elimination half-life to permit once-daily dosing 2. The medication comes as enteric-coated pellets designed to prevent degradation in the acidic stomach environment 1.
Important Clinical Distinction
While the terms SNRI and SSNRI are used interchangeably in the literature, they refer to the same drug class 4, 5. The "selective" designation emphasizes that these medications specifically target serotonin and norepinephrine reuptake, distinguishing them from older, less selective antidepressants like tricyclic antidepressants (TCAs).